Sun Pharmaceutical Acquires 100% of Innovcare Lifesciences in Strategic Move to Bolster Product Portfolio
Sun Pharmaceutical Industries Limited has entered into an agreement to acquire 100% of the outstanding shares of Innovcare Lifesciences Private Limited. The acquisition is set up as a strategic investment aimed at strengthening the product portfolio of Sun Pharma.The transaction involves cash consideration, and the total cost for acquiring the full stake in Innovcare stands at approximately Rs 271.2 Crores.
Innovcare Lifesciences Private Limited, based in Mumbai, specializes in the marketing, distribution, and sale of pharmaceutical drugs, nutraceutical, and cosmeceutical products. The company was incorporated on July 21, 2014, and operates exclusively within India.
Sun Pharma noted that this acquisition will not constitute a related party transaction, with no interest held by the promoter or promoter group in Innovcare.
Transaction Timeline and Scope
The agreement outlines that Sun Pharmaceutical Industries Limited will acquire all outstanding shares of Innovcare Lifesciences Private Limited for cash consideration. The tentative timeline provided indicates that the completion of this acquisition is expected on or before July 31, 2026.This strategic move falls under the Pharmaceuticals and Healthcare industry sector.
Financial Profile of Innovcare
Innovcare has demonstrated consistent revenue growth over the last three financial years. A brief look at its operating turnover is provided below:| Financial Year | Turnover (in INR Crores) |
|---|---|
| 2023-24 | 80.93 |
| 2024-25 | 86.09 |
| 2025-26 | 94.06 |
Sun Pharma views the acquisition of Innovcare as a move to strategically bolster its existing product offerings by integrating the capabilities and reach of the acquired entity.
SFL Stock Price Movement
On Friday, Sheela Foam Limited shares edged higher to close at ₹700.65, posting a 0.22% gain. The stock traded 259,025 shares during the session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.